Protagonist: Ph2 REVIVE hits primary endpoint (p=0.0003); Ph3 VERIFY enrollment completion expected 1Q 2024

Protagonist Therapeutics, Inc

Phase 2b FRONTIER 1 trial of JNJ-2113 in moderate-to-severe psoriasis completed; Phase 3 psoriasis study initiation planned.
Enrollment completion for Phase 3 VERIFY trial of rusfertide in polycythemia vera expected in 1Q 2024.
Phase 2 REVIVE study met primary endpoint with high statistical significance (p=0.0003); 69.2% responders vs 18.5% placebo.
Rusfertide showed rapid hematocrit control in PACIFIC study; safety profile generally well tolerated with no new signals.
New Phase 2b study of JNJ-2113 in ulcerative colitis planned for 4Q 2023; cash runway through end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.